Nu-Med Plus (Nu-Med Plus) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nu-Med Plus's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Nu-Med Plus ROCE % Historical Data

The historical data trend for Nu-Med Plus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus ROCE % Chart

Nu-Med Plus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-3,728.97

-482.56

Nu-Med Plus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Nu-Med Plus ROCE % Calculation

Nu-Med Plus's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.121	/	( ( (0.08 - 0.143)	+	(0.013 - 0.16) )	/ 2 )
	=	-0.121	/	( (-0.063	+	-0.147)	/ 2 )
	=	-0.121	/	-0.105
	=	115.24 %

Nu-Med Plus's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-0.084	/	( ( (0.013 - 0.16)	+	(0.009 - 0.178) )	/ 2 )
	=	-0.084	/	( ( -0.147	+	-0.169 )	/ 2 )
	=	-0.084	/	-0.158
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Nu-Med Plus (OTCPK:NUMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nu-Med Plus ROCE % Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nu-Med Plus (Nu-Med Plus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777

Website

https://www.nu-medplus.com

Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.

Executives

William C Hayde	director, officer: CEO	76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith	10 percent owner	P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl	director, officer: VP of Medical Marketing	P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen	officer: CFO, Sec, Treas, Prin Acct Off	455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait	10 percent owner	514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison	director, 10 percent owner, officer: Vice President of Technology	975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon	director, 10 percent owner, officer: Vice President of Operations	1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins	director, 10 percent owner, officer: CEO	455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111